Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Kaiser, Philipp D
Heitmann, Jonas S
Walz, Juliane S
Joos, Thomas O
MetadataShow full item record
AbstractThe humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis is required to understand the manifestation and progression of COVID-19, monitor seroconversion within the general population, and support vaccine development. The majority of currently available commercial serological assays only quantify the SARS-CoV-2 antibody response against individual antigens, limiting our understanding of the immune response. To overcome this, we have developed a multiplex immunoassay (MultiCoV-Ab) including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses. Compared to three broadly used commercial in vitro diagnostic tests, our MultiCoV-Ab achieves a higher sensitivity and specificity when analyzing a well-characterized sample set of SARS-CoV-2 infected and uninfected individuals. We find a high response against endemic coronaviruses in our sample set, but no consistent cross-reactive IgG response patterns against SARS-CoV-2. Here we show a robust, high-content-enabled, antigen-saving multiplex assay suited to both monitoring vaccination studies and facilitating epidemiologic screenings for humoral immunity towards pandemic and endemic coronaviruses.
CitationNat Commun. 2021 Mar 11;12(1):1577. doi: 10.1038/s41467-021-21609-2.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
- Comparison of 2 fully automated tests detecting antibodies against nucleocapsid N and spike S1/S2 proteins in COVID-19.
- Authors: Flinck H, Rauhio A, Luukinen B, Lehtimäki T, Haapala AM, Seiskari T, Aittoniemi J
- Issue date: 2021 Jan
- The complexities of SARS-CoV-2 serology.
- Authors: Houlihan CF, Beale R
- Issue date: 2020 Dec
- SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
- Authors: Guthmiller JJ, Stovicek O, Wang J, Changrob S, Li L, Halfmann P, Zheng NY, Utset H, Stamper CT, Dugan HL, Miller WD, Huang M, Dai YN, Nelson CA, Hall PD, Jansen M, Shanmugarajah K, Donington JS, Krammer F, Fremont DH, Joachimiak A, Kawaoka Y, Tesic V, Madariaga ML, Wilson PC
- Issue date: 2021 Jan 19
- A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2.
- Authors: Rusanen J, Kareinen L, Levanov L, Mero S, Pakkanen SH, Kantele A, Amanat F, Krammer F, Hedman K, Vapalahti O, Hepojoki J
- Issue date: 2021 Jan 20
- Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
- Authors: Yokoyama R, Kurano M, Morita Y, Shimura T, Nakano Y, Qian C, Xia F, He F, Kishi Y, Okada J, Yoshikawa N, Nagura Y, Okazaki H, Moriya K, Seto Y, Kodama T, Yatomi Y
- Issue date: 2021